The old adage that money doesn’t change everything could well be said of this year’s Top 10 U.S. biopharma clusters as listed by GEN. Nearly all regions saw significant increases in NIH funding (thanks to the $2 billion boost agreed upon by Congress for the current fiscal year) and in venture capital or “VC” funding (thanks to a market that was bullish on biopharma until this fall).